Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Astellas Pharma Inc. (ALPMY) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Astellas Pharma Inc. is one of 1000 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Astellas Pharma Inc. is currently sporting a Zacks Rank of #2 (Buy).Within the past quarter, the Zacks Consensus Estimate for ALPMY's full-year earnings has moved 25.6% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.According to our latest data, ALPMY has moved about 4.2% on a year-to-date basis. In comparison, Medical companies have returned an average of -3.1%. This means that Astellas Pharma Inc. is outperforming the sector as a whole this year.Another stock in the Medical sector, AngioDynamics (ANGO), has outperformed the sector so far this year. The stock's year-to-date return is 4.8%.Over the past three months, AngioDynamics' consensus EPS estimate for the current year has increased 22.5%. The stock currently has a Zacks Rank #1 (Strong Buy).Looking more specifically, Astellas Pharma Inc. belongs to the Medical - Drugs industry, which includes 162 individual stocks and currently sits at #63 in the Zacks Industry Rank. This group has lost an average of 3.9% so far this year, so ALPMY is performing better in this area.In contrast, AngioDynamics falls under the Medical - Instruments industry. Currently, this industry has 85 stocks and is ranked #75. Since the beginning of the year, the industry has moved -8.6%.Astellas Pharma Inc. and AngioDynamics could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Astellas Pharma Inc. (ALPMY): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks